Obesity and type 2 diabetes mellitus have been increasing worldwide, and are considered to be related to physical inactivity and dysregulated eating behavior. Although environmental factors are important in the progression of obesity, the contribution of adipose tissue dysfunction and related genetic factors have been less clear.

Adipose tissue is a metabolic and endocrine organ known to secrete a variety of bioactive molecules termed adipocytokines/adipokines, including fatty acids, adiponectin, leptin and interleukin‐6. Dysregulated production of adipocytokines in obesity is closely associated with dyslipidemia, insulin resistance and atherosclerosis. Adipocytes store energy as triglyceride. In the fasting state, the adipose tissue mobilizes fatty acids and glycerol by lipolysis to various tissues for energy expenditure. However, in obese adipose tissue, steady‐state (basal) lipolytic activity is high, and excessive flow of fatty acids and glycerol is involved in impaired lipid and glucose metabolism, particularly in the liver.

Adipose tissue mass is determined by the amount of stored and removed triglycerides in adipocytes. However, little is known about adipose lipid turnover in humans. Arner *et al*.[1](#jdi12950-bib-0001){ref-type="ref"} recently reported in *Cell Metabolism* that insufficient lipolysis in adipose tissue might be linked to future weight gain and impaired glucose metabolism. It has been shown that triglycerides are renewed six times during the average 10‐year lifespan of human adipocytes[2](#jdi12950-bib-0002){ref-type="ref"}. However, in obesity, adipose lipid turnover, reflected by the triglyceride removal rate, is decreased, whereas the amount of triglyceride stored each year is increased. Lipid removal rate correlates with cyclic adenosine monophosphate‐induced lipolysis, but not with basal lipolysis[2](#jdi12950-bib-0002){ref-type="ref"}.

Arner *et al*.[1](#jdi12950-bib-0001){ref-type="ref"} carried out comprehensive analysis of subcutaneous adipocytes obtained from two female cohorts before and after ≥10‐year follow up (Table [1](#jdi12950-tbl-0001){ref-type="table"}). High steady‐state (basal) and low stimulated lipolysis by isoprenaline, noradrenaline or dibutyryl cyclic adenosine monophosphate predicted future weight gain (odds ratio ≥4.6) and development of impaired glucose metabolism (odds ratio ≥3.2; Table [2](#jdi12950-tbl-0002){ref-type="table"})[1](#jdi12950-bib-0001){ref-type="ref"}. At study baseline, low expression levels of several lipolysis‐regulating genes, such as guanine nucleotide‐binding protein G(I)/G(S)/G(O) subunit gamma‐12 (GNG12), cyclic adenosine monophosphate‐dependent protein kinase type II‐β regulatory subunit (PRKAR2B), monoacylglycerol lipase (MGLL), fatty acid binding protein 4 (FABP4), and aquaporin 7 (AQP7), were found in adipose tissue of weight gainers. For example, AQP7, a glycerol channel in adipocytes, is associated with glycerol release from adipose tissue, and *Aqp*7 knockout mice developed insulin resistance and showed adipocyte hypertrophy[3](#jdi12950-bib-0003){ref-type="ref"}. Furthermore, human genetic variants of AQP7 have been linked to obesity and type 2 diabetes, suggesting that AQP7 might be a suitable pharmacological target for obesity and type 2 diabetes[4](#jdi12950-bib-0004){ref-type="ref"}. Arner *et al*.[1](#jdi12950-bib-0001){ref-type="ref"} also showed a lack of association between baseline fatty acid oxidation and weight change, and concluded that adipocyte hypertrophy at baseline was unlikely to be associated with future weight gain.

###### 

Clinical and adipocyte characteristics at first and second examinations

  Parameter                                                                 First examination   Difference between second and first examination or the number of participants at second examination                                         
  ------------------------------------------------------------------------- ------------------- ----------------------------------------------------------------------------------------------------- ------- -------------- -------------- --------
  Age (years)                                                               39 ± 6              38 ± 8                                                                                                0.69    13 ± 1         13 ± 1         0.22
  Bodyweight (kg)                                                           86 ± 17             93 ± 14                                                                                               0.15    −0.6 ± 3.3     13.1 ± 6.4     --
  BMI (kg/m^2^)                                                             31 ± 6              34 ± 5                                                                                                0.051   −0.2 ± 1.2     4.8 ± 2.3      --
  Physical activity (score)                                                 1.9 ± 0.7           1.8 ± 0.7                                                                                             0.54    0.2 ± 0.7      0.0 ± 1.0      0.35
  RQ                                                                        0.84 ± 0.05         0.84 ± 0.05                                                                                           0.86    N/A            N/A            --
  P‐glucose (mmol/L)                                                        5.1 ± 0.6           5.3 ± 0.5                                                                                             0.19    0.5 ± 0.5      1.0 ± 0.7      0.008
  S‐insulin (mU/L)                                                          9.8 ± 5.9           11.1 ± 4.7                                                                                            0.41    0.6 ± 6.5      8.5 ± 13.1     0.005
  HOMA‐IR                                                                   2.3 ± 1.4           2.7 ± 1.3                                                                                             0.30    0.43 ± 1.7     3.1 ± 4.7      0.0038
  P‐TG (mmol/L)                                                             1.1 ± 0.7           1.0 ± 0.4                                                                                             0.53    −0.26 ± 0.51   0.17 ± 0.31    0.002
  P‐HDL‐C (mmol/L)                                                          1.3 ± 0.4           1.3 ± 0.3                                                                                             0.48    0.2 ± 0.3      0.1 ± 0.2      0.26
  P‐TC (mmol/L)                                                             4.7 ± 0.8           4.6 ± 0.8                                                                                             0.49    −0.07 ± 0.84   0.07 ± 0.71    0.53
  IFG or type 2 diabetes mellitus (yes/no)                                  2/34                2/16                                                                                                  0.46    8/28           11/7           0.005
  Nicotine use (yes/no)                                                     6/30                2/16                                                                                                  0.59    3/33           7/18           0.56
  Pharmacological therapy (yes/no[†](#jdi12950-note-0001){ref-type="fn"})   0/36                0/18                                                                                                  --      8/28           6/12           0.58
  Fat cell volume (pL)                                                      678 ± 237           764 ± 181                                                                                             0.18    −96 ± 147      46 ± 156       0.0022
  Log basal lipolysis (μmol glycerol/2h/g lipid)                            −0.04 ± 0.24        0.14 ± 0.21                                                                                           0.007   −0.12 ± 0.36   −0.25 ± 0.25   0.19
  Log NA/basal lipolysis                                                    0.53 ± 0.25         0.36 ± 0.19                                                                                           0.008   −0.09 ± 0.27   0.07 ± 0.27    0.049
  Log ISO/basal lipolysis                                                   0.73 ± 0.27         0.52 ± 0.22                                                                                           0.005   0.06 ± 0.33    0.18 ± 0.24    0.20
  Log dcAMP/basal lipolysis                                                 0.66 ± 0.26         0.48 ± 0.19                                                                                           0.007   0.08 ± 0.30    0.18 ± 0.23    0.22
  Log ISO/NA lipolysis                                                      0.18 ± 0.12         0.16 ± 0.14                                                                                           0.50    0.16 ± 0.20    0.11 ± 0.12    0.36

Values are mean ± standard deviation or numbers, and compared by unpaired or paired *t*‐test and χ^2^‐test. ^†^Against diabetes, dyslipidemia or hypertension. BMI, body mass index; dcAMP, dibutyryl cyclic adenosine monophosphate; HDL‐C, high‐density lipoprotein‐cholesterol; HOMA‐IR, homeostasis model assessment‐insulin resistance; IFG, impaired fasting glucose; ISO, isoprenaline; N/A, not analyzed; NA, noradrenaline; P, fasting plasma; RQ, respiratory quotient; S, fasting serum; TC, total cholesterol; TG, triglycerides. Reproduced with permission from Arner *et al*. 2018^1^. Copyright and all rights reserved.
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###### 

Prospective values of lipolysis measures

  Parameter                      High basal                 Low NA/basal               Low ISO/basal             Low dcAMP/basal            High basal/Low stimulated
  ------------------------------ -------------------------- -------------------------- ------------------------- -------------------------- ---------------------------
  Weight gain                    6.7 (1.81--24.9); 0.002    4.6 (1.30--15.9); 0.013    5.9 (1.60--21.9); 0.004   4.6 (1.30--15.9); 0.013    7.4 (1.9--28.9); 0.002
  Type 2 diabetes mellitus/IFG   3.2 (0.90--11.6); 0.065    5.3 (1.34--20.4); 0.012    4.4 (1.17--16.9); 0.022   5.3 (1.35--20.4); 0.012    4.5 (1.12--18.1); 0.027
  Increased HOMA‐IR              11.9 (1.67--84.5); 0.008   10.6 (1.48--76.1); 0.012   9 (1.32--61.1); 0.017     23.8 (2.65--213); 0.0016   20 (2.2--181); 0.003

Subjects in cohort 1 were subdivided into high or low lipolysis measures based on median values. Composite results for individuals displaying high basal and concomitant low isoprenaline/basal are also detailed. Results are shown as odds ratios (95% confidence intervals); *P* values (using likelihood ratio test) for changes over time in individual clinical parameters. dcAMP, dibutyryl cyclic adenosine monophosphate; HOMA‐IR, homeostasis model assessment‐insulin resistance; IFG, impaired fasting glucose; ISO, isoprenaline; NA, noradrenaline.
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Steady‐state (basal) lipolysis is higher and hormone‐induced lipolysis is lower in the obese adipose tissue[5](#jdi12950-bib-0005){ref-type="ref"}. The study of Arner *et al*.[1](#jdi12950-bib-0001){ref-type="ref"} showed that, even at study baseline, higher steady‐state (basal) and lower stimulated lipolysis activity were linked to future weight gain. The authors stipulated that a high steady‐state (basal) lipolysis or insufficient lipolysis, which cannot be adequately accelerated by catecholamine stimulation, might shift the balance in lipid turnover towards uptake, which facilitates fat mass growth[1](#jdi12950-bib-0001){ref-type="ref"}.

Body fat distribution varies considerably among individuals. Irrespective of body mass index (\<25 or ≥25 kg/m^2^), visceral fat accumulation, which results from dysregulated eating behavior and physical inactivity, can lead to type 2 diabetes, dyslipidemia, hypertension and atherosclerotic cardiovascular diseases, conceptualized as the metabolic syndrome[6](#jdi12950-bib-0006){ref-type="ref"}. In contrast, subcutaneous fat mass/total fat mass is associated with a low risk of cardiovascular diseases. There is also a sex difference in body fat distribution; that is, men are more affected by visceral fat obesity and women are more affected by subcutaneous fat obesity[7](#jdi12950-bib-0007){ref-type="ref"}. It has been reported that the lipolytic effect of catecholamines is more pronounced in visceral than subcutaneous adipose tissue[8](#jdi12950-bib-0008){ref-type="ref"}. In contrast, the steady‐state (basal) lipolytic activity is higher in subcutaneous than visceral fat adipose tissue[5](#jdi12950-bib-0005){ref-type="ref"}. As the study by Arner *et al*.[1](#jdi12950-bib-0001){ref-type="ref"} is limited to subcutaneous fat in women, further studies are required in the future that include men and focus on fat distribution.

How can we combat low stimulated lipolytic activity? Endurance exercise training is reported to increase catecholamine‐stimulated adipocyte lipolysis[9](#jdi12950-bib-0009){ref-type="ref"}. Therefore, individuals with constitutionally low stimulated lipolytic activity might benefit from exercise in addition to a low caloric diet. Baseline measurement of lipolytic activity in adipose tissue or algorithm for estimation of fat cell lipolysis might be helpful for assessment of the risk for future weight gain and type 2 diabetes[1](#jdi12950-bib-0001){ref-type="ref"}.
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